Johnson & Johnson Ends Cusatuzumab License Deal With Argenx

By Colin Kellaher

Johnson & Johnson on Monday said it is ending its collaboration and license agreement with argenx SE for cusatuzumab, an investigational therapeutic antibody in development for the treatment of acute myeloid leukemia.

J&J's Janssen Pharmaceutical Cos. unit said the decision is based on its review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia, a cancer of the blood and bone marrow.

J&J in 2018 inked an agreement with Netherlands-based immunology company argenx to develop cusatuzumab that included a $300 million upfront payment and a $200 million equity investment.

Argenx, which regains worldwide rights to cusatuzumab, said interim data from a Phase 1b trial support continued development of the antibody in acute myeloid leukemia, and that it will study its options to enable a path forward.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

June 07, 2021 06:37 ET (10:37 GMT)

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024